DBV Technologies reported $248.12M in Assets for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Assets Change
DBV Technologies DBVT:US USD 248.12M 36.86M
Acadia Pharmaceuticals ACAD:US USD 602.49M 10.28M
Alnylam Pharmaceuticals ALNY:US USD 3.54B 204.84M
Amarin AMRN:US USD 908.3M 64.93M
Biocryst Pharmaceuticals BCRX:US USD 558.59M 48.06M
Biomarin Pharmaceutical BMRN:US USD 6.26B 118.2M
Esperion Therapeutics ESPR:US USD 312.83M 8.85M
Galectin Therapeutics GALT:US USD 17.91M 7.97M
Halozyme Therapeutics HALO:US USD 1.86B 83.15M
Insmed INSM:US USD 994.82M 58.54M
Intercept Pharmaceuticals ICPT:US USD 559.4M 60.81M
IONIS PHARMACEUT IONS:US USD 2.42B 34.16M
Neurocrine Biosciences NBIX:US USD 2.14B 137.7M
Ptc Therapeutics PTCT:US USD 1.58B 227.66M
Sarepta Therapeutics SRPT:US USD 3.16B 159.3M
Ultragenyx Pharmaceutical RARE:US USD 1.62B 297.85M
United Therapeutics UTHR:US USD 5.78B 238.3M
YTE INCY:US USD 5.51B 191.18M